ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics (blood levels) and safety of
chimeric (ch) 14.18 manufactured by two independent drug makers (United Therapeutics [UTC] or
the National Cancer Institute [NCI]).